Advertisement

Drugs

, Volume 49, Supplement 2, pp 29–35 | Cite as

Mechanisms of Resistance to Fluoroquinolones: State-of-the-Art 1992–1994

  • Laura J. V. Piddock
State-Of-The-Art Presentations

Summary

This paper gives an update on the mechanisms of bacterial resistance to fluoroquinolones. The laboratory techniques currently used to determine the mechanism(s) of resistance are outlined, including the use of restriction fragment length polymorphism and single-stranded conformational polymorphism analysis of mutations in gyrA. Alterations in gyrA have continued to be the most reported cause of resistance, with high level resistance due to 2 or more mutations in this gene. Recently, mutations in gyrA of Mycobacterium tuberculosis and Campylobacter jejuni have been described. Complementation studies with plasmid encoded cloned gyrB from Escherichia coli suggest that high fluoroquinolone resistance (minimum inhibitory concentration = 32 mg/L) in Salmonella typhimurium can be due to mutation in both gyrA and gyrB.

Decreased fluoroquinolone accumulation into E. coli has been shown to be due to mutations in a number of genes at different loci. Current interest has focused upon the marRAB and soxRS loci, with mutations in genes of either loci giving rise to decreased susceptibility to several unrelated drugs, including fluoroquinolones, tetracycline, chloramphenicol and some β-lactams, and decreased expression of OmpF. The genetic characterisation of fluoroquinolone efflux from Staphylococcus aureus has shown that efflux occurs in both fluoroquinolone-susceptible and -resistant bacteria. The most likely cause of resistance is overexpression of NorA, giving rise to increased efflux. Recently, 2 efflux systems in Pseudomonas aeruginosa have been proposed, MexA-MexB-OprK and MexC-MexD-OprM, conferring decreased susceptibility to fluoroquinolones, tetracycline, chloramphenicol and some β-lactams.

To date, most clinical fluoroquinolone resistance has been due to mutations in gyr A; however, with the continued increase in the use of these agents bacteria will continue to employ different tactics to evade their action. It is likely that high level fluoroquinolone resistance will emerge in previously susceptible species because of several mutations in one or several genes.

Keywords

Minimum Inhibitory Concentration Fluoroquinolones Norfloxacin Nalidixic Acid Antimicrob Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Piddock LJV. Resistance to quinolones and fluoroquinolones. In: Bryan LE, editor. Handbook of experimental pharmacology: microbial resistance to drugs. Heidelberg: Springer-Verlag, Chapter 8, 1989: 169-92Google Scholar
  2. 2.
    Cambau E, Gutmann L. Mechanisms of resistance to quinolones. Drugs 1993; 45 Suppl. 3: 15–23PubMedCrossRefGoogle Scholar
  3. 3.
    Robillard N. Broad host range gyrase A gene probe. Antimicrob Agents Chemother 1990; 34: 1889–94PubMedCrossRefGoogle Scholar
  4. 4.
    Heisig P, Wiedemann B. Use of a broad-host-range gyrA plasmid for genetic characterisation of fluoroquinolone-resistant Gram-negative bacteria. Antimicrob Agents Chemother 1991; 35: 2031–6PubMedCrossRefGoogle Scholar
  5. 5.
    Heisig P, Tschorny R. Characterisation of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 1994; 38: 1284–91PubMedCrossRefGoogle Scholar
  6. 6.
    Tokue Y, Sugano K, Saito D, et al. Detection of novel mutations in gyrA gene of Staphylococcus aureus by nonadioisotopic single-strand conformation polymorphism analysis and direct DNA sequencing. Antimicrob Agents Chemother 1994; 38: 310–428CrossRefGoogle Scholar
  7. 7.
    Takiff HE, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of M. tuberculosis gyrA and gytrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773–80PubMedCrossRefGoogle Scholar
  8. 8.
    Wang Y, Huang WM, Taylor DE. Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterisation of quinolone resistance mutations. Antimicrob Agents Chemother 1993; 37: 457–63PubMedCrossRefGoogle Scholar
  9. 9.
    Cullen ME, Wyke AW, Kuroda R, et al. Cloning and characterisation of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob Agents Chemother 1989; 33: 886–94PubMedCrossRefGoogle Scholar
  10. 10.
    Yamagishi J, Yoshida H, Yamayichi M, et al. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet 1986; 204: 367–73PubMedCrossRefGoogle Scholar
  11. 11.
    Heisig P. High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyrA and gyrB genes. J Antimicrob Chemother 1994; 32: 367–77CrossRefGoogle Scholar
  12. 12.
    Piddock LJV. Mechanism of quinolone uptake into bacterial cells. J Antimicrob Chemother 1991; 27: 399–405PubMedCrossRefGoogle Scholar
  13. 13.
    Hirai K, Aoyama H, Suzue S, et al. Isolation and characterisation of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother 1986; 30: 248–53PubMedCrossRefGoogle Scholar
  14. 14.
    Hooper D, Wolfson J, Souza KS, et al. Genetic and biochemical characterisation of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother 1986; 29: 638–44CrossRefGoogle Scholar
  15. 15.
    Greenberg JT, Chou JH, Monach PA, et al. Activation of oxidative stress genes by mutations at the soxQ/cfxB/marA locus of Escherichia coli. J Bacteriol 1991; 173: 433–9Google Scholar
  16. 16.
    Hooper DC, Wolfson JS, Souza KS, et al. Mechanisms of quinolone resistance in Escherichia coli: characterisation of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob Agents Chemother 1989; 33: 283–90PubMedCrossRefGoogle Scholar
  17. 17.
    Hrebenda J, Heleszko H, Brostek K, et al. Mutation affecting resistance of Escherichia coli K12 to nalidixic acid. J Gen Microbiol 1985; 131: 2285–92PubMedGoogle Scholar
  18. 18.
    Miller PF, Gambino LF, Sulvik MC, et al. Genetic relationship between soxRS and mar loci in promoting multiple antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 1994; 38: 1773–9PubMedCrossRefGoogle Scholar
  19. 19.
    Ariza RR, Cohen SP, Bachhawat N, et al. Repressor mutations in the maRAB operon that activate oxidative stress genes and multiple antibiotic resistance in Escherichia coli. J Bacteriol 1994; 176: 143–48PubMedGoogle Scholar
  20. 20.
    Cohen SP, Hooper DC, Wolfson JS, et al. Endogenous active efflux of norfloxacin in susceptible E. coli. Antimicrob Agents Chemother 1988; 32: 1187–91PubMedCrossRefGoogle Scholar
  21. 21.
    Yoshida H, Bogaki M, Nakamura S, et al. Nucleotide sequence and characterisation of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 1990; 172: 6942–9PubMedGoogle Scholar
  22. 22.
    Yoshida H, Kojima T, Inoue M, et al. Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35: 368–70PubMedCrossRefGoogle Scholar
  23. 23.
    Oshita Y, Hiramatsu K, Yokota T. A point mutation in the norA gene is responsible for quinolone resistance in Staphylococcus aureus. Biochem Biophys Res Commun 1990; 172: 1028–34CrossRefGoogle Scholar
  24. 24.
    Kaatz GW, Seo SM, Ruble CA. Efflux mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37: 1086–94PubMedCrossRefGoogle Scholar
  25. 25.
    Poole K, Krebes K, McNally K, et al. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 1993; 175: 7363–72PubMedGoogle Scholar
  26. 26.
    Li X-Z, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol and norfloxacin. Antimicrob Agents Chemother 1994; 38: 1732–41PubMedCrossRefGoogle Scholar
  27. 27.
    Nakashini N, Yoshida S, Wakebe H, et al. Mechanisms and clinical resistance to fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35: 2562–7CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Laura J. V. Piddock
    • 1
  1. 1.Antimicrobial Agents Research Group, Department of InfectionUniversity of BirminghamBirminghamEngland

Personalised recommendations